For citations:

Kolbin A.S., Kurylev A.A., Balykina Yu.E., Proskurin M.A. Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2017;(1):11-19. (In Russ.)